Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 9/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232070 | 0.79 | PDE3B (0.55) | PDE2APDE3BPDE3ACYP3A4 | |
| SCHEMBL19836475 | 0.75 | AURKA (0.42) | POLBPGRMTORMAOBPIM1 | |
| SCHEMBL31425656 | 0.70 | PGR (0.43) | POLBPGRMTORCYP3A4CYP2B6 | |
| SCHEMBL9963175 | 0.70 | POLB (0.46) | POLBPGRMTORPDE2APDE3B | |
| SCHEMBL17807828 | 0.69 | MAOB (0.44) | POLBPGRMTORCYP3A4CYP2B6 | |
| SCHEMBL15749623 | 0.66 | POLB (0.49) | POLBPGRMAOB | |
| SCHEMBL15740791 | 0.66 | POLB (0.49) | POLBPGRMAOB | |
| SCHEMBL481934 | 0.66 | MTOR (0.58) | POLBMTORCYP3A4CYP2B6 | |
| SCHEMBL1496451 | 0.65 | POLB (0.56) | POLBPGR | |
| SCHEMBL20987129 | 0.65 | PGR (0.60) | POLBPGRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748429-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130096130-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130053570-A1 | CGRP Receptor Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053570-A1 | CGRP Receptor Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | POLB 3196/4885PGR 97/4885MTOR 1595/4885 |
| US-20130053570-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | POLB 3315/4885PGR 92/4885MTOR 1922/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | POLB 3196/4885PGR 97/4885MTOR 1595/4885 |
| US-20130096130-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | POLB 3315/4885PGR 92/4885MTOR 1922/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | POLB 3315/4885PGR 92/4885MTOR 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.